



Demographics and socioeconomic

Total Population (in 1000) (2020)	9,904.61
Population <1 year of age (in 1000) (2020)	211.35
Population 1 year of age (in 1000) (2020)	206.17
Population <5 years of age (in 1000) (2020)	1,017.02
Women of childbearing age (in 1000) (2020)	8,494.72
Infant Mortality Rate (per 1000 live births) (2016)*	22.8
Gross national income (US\$ per capita) current value (2020)	2,200.0
National Health Expenditure Public (2018)	2.8
National Health Expenditure Private (2018)	4.0

* data have one or more of the following limitations: coverage of maternal deaths and live births, differences in the maternal death definition, different denominators used, the analysis of only confirmed maternal deaths, and coverage of infant and neonatal deaths

Immunization system highlights

- There is a comprehensive multi-year plan for immunization covering 2020-2021.
- A standing national technical advisory group on immunization (NITAG) with formal written terms of reference exists. The group met 3 times in 2020.
- 97% of spending on routine immunization is financed using government funds.
- 95% of spending on vaccine purchases is financed using government funds.
- A national nominal electronic immunization registry is in place.


Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	1999
Hepatitis B	2000
HPV	2016
Influenza	2003
MMR1	1997
MMR2	2018
Pentavalent	2000
Pneumococcal Conjugate	2011
Rotavirus	2009
Tdap	
Tetavalent DPT-Hib or DPT-HepB	
Yellow Fever	

Immunization Schedule

HND	Doses					
	1	2	3	4	5	6
BCG	B					
HepB pediatric	B					
DTP-Hib						
DTP-Hib-HepB	M2	M4	M6			
DTP-Hib-IPV						
DTP-Hib-HepB-IPV						
DTP				M18	Y4	
Influenza pediatric	M24-Y17					
IPV	M2	M4				
OPV			M6	M18		
MMR	M12	M18				
Pneumoco conjugate	M2	M4	M6			
Rotavirus	M2	M4				
Td	Y11					
Tdap	1st contact					
HPV						

Vaccination Coverage




Surveillance indicators

Acute flaccid paralysis (AFP)	2020
Number of AFP suspected cases	50
AFP rate per 100,000 population <15 years old	1.65
% of cases with 1 adequate samples	90
% of cases investigated within <48 hours	82
% sites reporting	91


Measles-rubella (MR)	2020
Number of MR suspected cases	118
% of cases with adequate investigation	97
% of cases with adequate blood samples	100
% of samples received in laboratory <=5 days	85
% of laboratory samples results <=4 days	99




Polio3 coverage and AFP rate per 100,000 children <15 years of age




DTP3 coverage and number of reported diphtheria and pertussis cases




Number of tetanus (no neonatal) and neonatal tetanus cases



Proportion of municipalities by coverage range with DTP3 in children <1 years of age



DTP1-DTP3 and DTP1-MMR1 Dropout Rate



Legend
 NB/nb-newborn
 M/m-month
 Y/y-year
 WCBA-women of childbearing age
 ● with stockout
 ● no stockout
 ○ no data available

Vaccine Stockout

HND	2013	2014	2015	2016	2017	2018	2019	2020
AD syringes	●	●	●	●	●	●	●	●
BCG	●	●	●	●	●	●	●	●
Disposable syringes	●	●	●	●	●	●	●	●
DTP	●	●	●	●	●	●	●	●
HepB	●	●	●	●	●	●	●	●
Hib	●	●	●	●	●	●	●	●
Influenza	●	●	●	●	●	●	●	●
IPV	●	●	●	●	●	●	●	●
Measles	●	●	●	●	●	●	●	●
Pneumo. conjugate	●	●	●	●	●	●	●	●
Polio	●	●	●	●	●	●	●	●
Reconst. syringes	●	●	●	●	●	●	●	●
Rotavirus	●	●	●	●	●	●	●	●
Safety boxes	●	●	●	●	●	●	●	●
Tdap	●	●	●	●	●	●	●	●
TT	●	●	●	●	●	●	●	●
Yellow fever	●	●	●	●	●	●	●	●